This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Efficacy and safety of oral SK3530 for the treatment of erectile
dysfunction in Korean men: a multicenter, randomized,
double-blind, placebo-controlled, fixed dose, parallel group clinical trial
Jae-Seung Paick1, Hyung-Ki
Choi2, Sae-Chul Kim3, Tai-Young
Ahn4, Je-Jong Kim5, Jong-Kwan
Park6, Kwang-Sung Park7, Sung-Won
Lee8, Sae-Woong Kim9, Kwanjin
Park10, Hyonggi Jung11, Nam-Cheol
Park12
1Department of Urology, Seoul National University Hospital, Seoul 110-744, Korea;
2Department of Urology, Yonsei University Yongdong Severance Hospital, Seoul 135-720, Korea;
3Department of Urology, Chung-ang University Yongsan
Hospital, Seoul 140-757, Korea; 4Department of Urology, University of Ulsan Asan Medical Center, Seoul 138-736, Korea;
5Department of Urology, Korea University Anam Hospital, Seoul 136-705,
Korea; 6Department of Urology, Chonbuk
National University Hospital, Jeonju 561-712, Korea;
7Department of Urology, Chonnam National University
Hospital, Gwangju 501-757, Korea; 8Department of Urology, Sungkyunkwan University Samsung Medical Center, Seoul 135-710,
Korea; 9Department of Urology, Catholic University St. Mary's Hospital, Seoul 150-713, Korea;
10Department of Urology, Korea Cancer Center Hospital, Seoul 139-706, Korea;
11Department of Biostatistics, Seokyeong University, Seoul
136-704, Korea; 12Department of Urology, Pusan National University Hospital, Busan 602-739, Korea
Abstract
Aim:
Keywords:
Correspondence to: Prof. Jae-Seung Paick, MD, PhD, Department of Urology, Seoul National University, College of Medicine, Seoul
110-744, Korea.
Tel: +82-2-072-2422 Fax: 82-2-762-2428 E-mail: jspaick@snu.ac.kr
Received 2008-02-22 Accepted 2008-04-21
DOI: 10.1111/j.1745-7262.2008.00422.x
1 Introduction
Erectile dysfunction (ED) is highly prevalent in Asian
men [1], and can be distressing because of its effect on
self-esteem, quality of life and interpersonal relationships
[2, 3]. Three major type 5 phosphodiesterase (PDE5)
inhibitors (PDE5Is), sildenafil, tadalafil and vardenafil,
have been shown to be effective in treating ED of
varying functional severity and etiology [4_6].
However, a substantial number of patients are believed to
discontinue treatment in the long term [7_9]. The main reason
for the poor compliance rate proved to be the lowered
efficacy that did not meet patients' expectations [9]. If
one PDE5I does not satisfy a patient's expectations, the
availability of another PDE5I might provide a better
opportunity to find the suitable agent that meets their needs.
SK3530 (2-(5-(4-(2-hydroxyethyl) piperazin-1-ylsulfonyl)-2-n-propoxyphenyl)-5-ethyl-7-n-propyl-3,5-
dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one dihydrochloride)
is a novel pyrrolopyrimidinone compound and a potent
and reversible PDE5I [10_11]. Several key clinical
pharmacokinetic and pharmacodynamic data have revealed
that SK3530 has acceptable pharmacologic properties
(Table 1). In particular, the selectivity ratios, which
express the x-fold differences in inhibitory activity for a
specific PDE compared with PDE5, has revealed comparable selectivity of SK3530 with other conventional
PDE5Is. A previous preclinical study revealed that the
IC50 of PDE5 for SK3530 is 10-fold lower than that of
sildenafil, a protodrug of PDE5I [10]. In contrast, its
inhibitory effects on other phosphodiesterases, such as
PDE1 and PDE11, are much lower than those of sildenafil
(Table 1) [12]. Moreover, a phase I study revealed that
SK3530 is well tolerated at daily doses of up to 200 mg
in healthy volunteers (COVANCE, unpublished data, 2003). Thus, the aim of the present trial was to evaluate
the effect of on-demand SK3530 therapy at fixed doses
(50, 100 and 150 mg) in Korean men with a broad range
of ED severity, and to determine the optimal dose with
respect to effectiveness and patient tolerance.
2 Materials and methods
2.1 Study design
This phase II, multicenter, randomized, double-blind,
placebo-controlled, four-arm, parallel group, fixed dose
comparison of 50, 100 and 150 mg SK3530
vs. placebo consisted of three parts: 1) a 4-week run-in period
without any ED treatment; 2) randomization to 8 weeks of
treatment with SK3530 or placebo; and 3) a 1-week
follow-up period for continued adverse event monitoring.
The eligible patients were men aged 19_70 years with
ED, defined as an inability to achieve or maintain a penile
erection sufficient for satisfactory sexual intercourse,
evident for a period longer than 6 months. To be
enrolled in the treatment phase of the study, the patients
were required to have experienced a 50% or greater
failure rate in maintaining an erection sufficient to complete
intercourse on at least four separate attempts during the
4-week treatment-free baseline period. The patients were
excluded from eligibility if they were determined by an
investigator to have experienced a serious
cardiovascular condition within the previous 6 months (e.g.,
myocardial infarction, unstable angina, a significant
electrocardiograph conduction defect, congestive heart failure
of New York Heart Association class 2 or greater, or a
stroke), or a systolic blood pressure > 170 mmHg or
< 90 mmHg, or a diastolic blood pressure > 100 mmHg
or < 50 mmHg, or if they were being treated with nitrates.
Other exclusion criteria included anatomic abnormalities
of the penis that could impair sexual intercourse,
hypoactive sexual desire, a history of radical prostatectomy, ED after spinal cord injury, retinitis
pigmentosa, chronic liver disease, major hematologic
disorder, poorly controlled diabetes (hemoglobin A1c
greater than 12 %), or a history of peptic ulcer disease
within 1 year. Any patients who had experienced
previous ineffective treatment with sildenafil, vardenafil, or tadalafil
were also excluded. During the treatment period, the use of
anti-androgens, anticoagulants, androgens, drugs
affecting cytochrome P450 3A4 (CYP3A4) metabolism, or
trazodone hydrochloride were not allowed. The study
was conducted at 10 tertiary-care, academically affiliated
investigative sites in Korea. The first patient was enrolled
in October 2004, and the study was completed in June
2005. The ethics committees of the participating
institutions approved the final protocol, amendments, and the
informed consent document.
2.2 Treatment
Medical history, a physical examination, laboratory
safety tests and an electrocardiogram were carried out
during each screening visit. Patients who met all
enrolment criteria were randomly allocated to 8 weeks of
on-demand treatment. The patients were instructed to take
the study medication approximately 1 h before intended
sexual intercourse. It was recommended that the drug
should be taken at least 1 h after a meal. Medication use
was monitored using patient medication/outcome diaries,
and the study personnel counted the number of used pills
during the assessment visits.
2.3 Measures
Erectile function was measured using the
International Index of Erectile Function (IIEF) and the Sexual
Encounter Profile (SEP) patient diary. Patients
completed the IIEF at the end of the run-in period and at the
end of each 4-week treatment period. The erectile
function (EF) domain scores at the start of the run-in period
were used to determine the baseline ED severity.
Patients recorded every sexual attempt in an SEP diary.
Global assessment question (GAQ) scores were also assessed.
The primary efficacy measures were changed in the
response to IIEF question 3 (Q3: Freguency of penetration) and question 4 (Q4: Freguency of maintained
erection). The secondary efficacy end-points were
changed between baseline and week 8 in the IIEF EF
domain scores, the percentage of "yes" responses to SEP
Q2 (penetration), SEP Q3 (successful intercourse) and
the GAQ score.
At each patient visit, a safety assessment was
carried out that included the recording of adverse events
and vital signs. A physical examination with routine
laboratory testing was carried out at randomization and at
every treatment visit.
2.4 Statistical analysis
An intent-to-treat analysis of each of the efficacy
variables included all patients with a baseline and at least
one post-baseline observation. The
last-observation-carried-forward imputation method was used for missing
data. Only variable age was significantly different
between the placebo group and each of the SK3530 groups.
Therefore, the ANCOVA method, using age and baseline
as covariates, was used to evaluate the primary efficacy
end-points and all secondary end-points, except for the
GAQ.
The GAQ was assessed using the
χ2-test. The testing of the hypotheses included comparisons of each
SK3530 dosage group with placebo; therefore,
Bonferroni's adjustment was used. Statistical significance was
accepted at the P < 0.05 level.
The number of patients needed for this study was
determined by both primary efficacy variables, IIEF Q3
and Q4. The sample size calculations assumed a
standard deviation of 1.06 for Q3 and 1.22 for Q4, as
indicated in a previous Korean study on sildenafil [13].
Treatment differences considered to be clinically significant
were awarded 1.6 and 1.7 points for each question.
With approximately 23 valid patients per group, this
study had the power of approximately 90% for the two
questions. Allowance for a 20% withdrawal rate required
a total of 116 randomized patients for efficacy analysis,
with 29 per group. The safety analysis included all
patients who had taken the drug at least once. Changes
from baseline in the continuous safety variables (laboratory
analysis and vital signs) were evaluated by ANOVA.
Between groups, comparisons of treatment-emergent
adverse event frequencies were conducted using the
χ2-test. Baseline demographics in the SK3530 and placebo
groups were compared using anova for continuous variables and the
χ2-test for categorical variables.
3 Results
3.1 Patient population and demographics
A total of 119 men at 10 study centers completed the
baseline evaluations and were randomized for treatment
with placebo (n = 30) or SK3530 at 50 mg
(n = 30), 100 mg (n = 30), or 150 mg
(n = 29). During the 8 weeks of therapy, five men (4.2%) withdrew from the
study: three men (one each in the placebo, 100 mg and
150 mg groups) committed a protocol violation and were
excluded; and two men (one each in the 50 mg and
100 mg groups) withdrew because of adverse events. A
total of 119 and 116 men were valid for the safety and
intent-to-treat analyses, respectively (Figure 1).
At baseline, no clinically or statistically meaningful
differences were found among the treatment groups with
respect to any demographic or clinical variables except
age (P = 0.02). The mean age of the placebo group was
lower than that of the SK3530 groups. However, there
were no significant differences in age distribution as a
categorical variable (P = 0.46; Table 2).
Overall, patients were diagnosed as having ED for a
mean of 50.9 months before screening. Of the 119 study
subjects, 46 (38.7%) had had previous experience with
a PDE5I. However, no significant difference was found
among the study groups in this respect. In addition, the
distribution of comorbid diseases was not statistically
different between treatment groups (P = 0.46 by Fisher's
exact test; Table 2).
3.2 Efficacy and treatment satisfaction
At baseline, the mean EF domain scores ranged from
13 to 15 and there were no significant differences in
severity of ED among the groups. After 8 weeks of
treatment, the primary efficacy measures, IIEF Q3 and
Q4, indicated a significant positive effect for all SK3530
doses compared with placebo (P < 0.01; Figure 2). For
those taking 100 mg SK3530, the mean Q3 score
increased from 2.6 at baseline to 4.4 at week 8, and the
mean Q4 score increased from 1.7 at baseline to 3.9 at
the same time point.
Similar results were obtained for the secondary
efficacy measures (Figure 3). The change from baseline to
end-point on the IIEF EF domain (maximal score 30)
was 8.4, 10.7 and 8.2 for the 50, 100 and 150 mg groups,
respectively, compared with 2.3 for placebo
(P < 0.01). In addition, SK3530 significantly improved the
percentage of successful penetrations (SEP Q2) and successful
intercourse completions (SEP Q3) compared with placebo. In the SK3530 treatment groups, the mean SEP
Q2 score increase ranged from 28.4% to 37.9% compared with 8.3% in the placebo group
(P < 0.01). The range of the SEP Q3 increases was 44.9% to 63.2%,
significantly greater than that of placebo (18.6%,
P < 0.05).
The superior efficacies of these doses were
maintained during treatment. The beneficial effect of SK3530
was apparent by GAQ analysis (Figure 3). Of the
intent-to-treat group, the proportion of affirmative responders
to the GAQ was significantly greater for the three SK3530
groups than for the placebo group (P < 0.01). At the
end of the study, 75.9% of the 50 mg group, 86.2% of
the 100 mg group, and 82.1% of the 150 mg group
described a positive response to the GAQ
vs. 34.5% of the placebo group.
SK3530 was able to induce normal EF (EF domain score greater than 25), irrespective of baseline ED severity.
After 8 weeks of treatment, 36 men (42.3%) in the
treatment group (7 [24.1%] in the 50 mg group, 15 [51.7%]
in the 100 mg group, and 14 [48.3%] in the 150 mg
group) achieved normal EF compared with 5 men (17.2%) in the placebo group. For those who regained
erectile function, 14 (50.0%), 16 (40%), and 6 (28.6%) had
mild, moderate, and severe ED at baseline, respectively.
3.3 Safety
In general, SK3530 was well tolerated at all given
doses. Although the 150 mg group experienced
significantly more treatment-emergent adverse events, all
adverse events were mild or moderate in intensity (Table
3). The most common treatment-emergent adverse events
were 13 cases (10.9%) of facial flushing, 9 (7.6%) of
headache, and 3 (2.5%) of dizziness and eye redness.
Two men withdrew from the study because of adverse
events (one in the 50 mg group and one in the
100 mg group). No clinically significant changes in the
laboratory parameters or vital signs occurred.
4 Discussion
The results of this study indicated that SK3530
dosages of 50, 100 and 150 mg are significantly superior to
placebo for the treatment of ED, as determined by the
primary study end-points of IIEF Q3 and Q4. In both
questions, the mean increases from baseline ranged from
1.6 to 2.2, significantly greater than that for placebo
(range, 0.2_0.7). Also, all doses of SK3530 were
significantly superior to placebo for the various secondary
study end-points (EF domain score, diary-recorded
success rates for penetration and maintenance of erection
during intercourse, and the GAQ).
The results are quite comparable to those of a
previous phase III trial of sildenafil in a similar population.
Choi et al. [13] reported results after 8 weeks of sildenafil
treatment with a flexible dosing regimen. The changes
in IIEF Q3 and Q4 from baseline were 1.6 and 1.9, respectively. Treatment-related adverse events were
observed in 56% of the sildenafil arm. Our study adopted
a fixed dose regimen and included 39% of patients who
had experienced other PDE5Is. Comparison with the
results from the previous Korean study supports the
belief that SK3530 might be at least as efficacious as
sildenafil.
One of the interesting findings was that SK3530
enabled approximately 42% of patients to achieve normal
EF; 50% of patients with mild ED and up to 29% of patients with severe ED who received SK3530 achieved
normal EF (as determined from EF domain scores greater
than 25). As was stressed by Mulhall [14], the
percentage of those regaining normal EF can be clinically
meaningful when comparing the efficacy of the drug evaluated.
Despite the difference in dosing design and treatment
duration, our results were comparable with previous
trials of vardenafil and tadalafil [15, 16]. SK3530 was well
tolerated. The adverse events often noted with its use,
flushing, headache, dizziness, and eye redness, were
expected from the pharmacology of PDE5Is [17] and the
results from clinical trials of other PDE5Is [15, 16]. All
of the adverse events recorded for patients in the present
trial were mild or moderate in severity and typically
resolved with continued use of the drug. Only two
patients discontinued during the study period because of
adverse events. Given the nature of fixed dosing, which
disallowed dose reductions resulting from poor tolerability, this finding might be additional evidence of
the safety of SK3530.
Concerns might be raised regarding the benefit of a
new PDE5I with similar efficacy and safety to
pre-existing ones. However, a number of studies have indicated
that preference for a medication depends on factors other
than efficacy, safety and tolerability [12, 18]. Besides
efficacy and safety, preference could be determined by
factors such as mode of action, duration, food interaction,
and cost. Therefore, we believe that the addition of a
new PDE5I that has a unique pharmacologic profile would
benefit someone that was not satisfied with their current
medication.
Concurrent medical diseases such as hypertension
and diabetes could affect the response to PDE5Is.
Therefore, the number of patients with various comorbidities should be equally distributed between the
tested groups. This is not always the case, especially in
a trial with a small number of patients. Fortunately, each
group in this study was balanced in terms of the number
of patients with comorbidities. If there is any concern
about unequal distribution between groups regarding the
number or severity of comorbidities, the use of validated
comorbidity indices, such as the Charlson comorbidity
index [19], might be of help .
Another important aim of this phase II study was to
determine the optimal dosage of SK3530. The efficacy
and safety results showed that 100 mg and 50 mg were
associated with the greatest efficacy and lowest adverse
events, respectively. Thus, it would be rational to
examine the efficacy and safety of 50 mg and 100 mg dosing
in a future phase III study.
This multicenter, randomized, double-blind,
placebo-controlled phase II trial showed that SK3530 safely
improved all efficacy parameters of erection in a broad
population of men with ED of varying etiologies and severity.
The most efficacious and safest doses were determined
to be 100 mg and 50 mg, respectively.
Acknowledgment
All authors have had full access to all data in the
study and take responsibility for its integrity and the
accuracy of the data analysis. This research was supported
by SK Chemical Corporation (Seoul, Korea).
References
1 Tan HM, Low WY, Ng CJ, Chen KK, Sugita M, Ishii N,
et al. Prevalence and correlates of erectile dysfunction (ED) and
treatment seeking for ED in Asian men: the Asian Men's
Attitudes to Life Events and Sexuality (MALES) study. J Sex
Med 2007; 4: 1582_92.
2 Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A,
Fernandez A, Burgos R, Rejas J. Male erectile dysfunction
and health-related quality of life. Eur Urol 2003; 44: 245_53.
3 Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS.
On life satisfaction in male erectile dysfunction. Int J Impot
Res 1997; 9: 141_8.
4 Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type
5 inhibitors: the day after. Eur Urol 2007; 51: 75_88.
5 Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, Wang
WC, et al. Efficacy and safety of on demand tadalafil in the
treatment of East and Southeast Asian men with erectile
dysfunction: a randomized double-blind, parallel,
placebo-controlled clinical study. Asian J Androl 2006; 8: 685_92.
6 Martin-Morales A, Haro JM, Beardsworth A, Bertsch J,
Kontodimas S; EDOS Group. Therapeutic effectiveness
and patient satisfaction after 6 months of treatment with
tadalafil, sildenafil, and vardenafil: results from the erectile
dysfunction observational study (EDOS). Eur Urol 2007;
51: 541_50.
7 Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett
AL, Jarow JP. Clinical efficacy of sildenafil citrate and
predictors of long-term response. J Urol 2003; 170: 503_6.
8 Son H, Park K, Kim SW, Paick J. Reasons for discontinuation
of sildenafil citrate after successful restoration of erectile
function. Asian J Androl 2004; 6: 117_20.
9 Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens
HG. Incidence and determinants of sildenafil (dis)continuation:
the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14:
259_65.
10 Shin HI, Lee J, Kim DK. Synthesis of
5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-n-propoxyphenyl}-
7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin
-4-one 2HCl (14C-SK3530.2HCl). J Label Compd Radiopharm
2006; 49: 1141_9.
11 Lee J, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism
and excretion of
5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo
[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun
Mass Spectrom 2007; 21: 1139_49.
12 Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML,
Loughney K, et al. Factors associated with preference for
sildenafil citrate and tadalafil for treating erectile dysfunction
in men na?ve to phosphodiesterase 5 inhibitor therapy: post
hoc analysis of data from a multicentre, randomized,
open-label, crossover study. BJU Int 2007; 100: 122_9.
13 Choi HK, Ahn TY, Kim JJ, Kim SC, Paick JS, Suh JK
et al. A double-blind, randomised- placebo, controlled, parallel group,
multicentre, flexible-dose escalation study to assess the efficacy
and safety of sildenafil administered as required to male
outpatients with erectile dysfunction in Korea. Int J Impot
Res 2003; 15: 80_6.
14 Mulhall JP. Deciphering erectile dysfunction drug trials. J
Urol 2003; 170: 353_8.
15 Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier
M, Taylor T et al. Vardenafil for treatment of men with erectile
dysfunction: efficacy and safety in a randomized, double-blind,
placebo-controlled trial. J Androl 2002; 23: 763_71.
16 Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang
C, et al. Efficacy and safety of tadalafil in a Western European
population of men with erectile dysfunction. BJU Int 2004;
94: 871_7.
17 Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of
pharmacokinetics and pharmacodynamics in
phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19: 253_64.
18 Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, Min KS,
et al. Treatment preferences in men with erectile dysfunction: an
open label study in Korean men switching from sildenafil citrate
to tadalafil. Asian J Androl 2007; 9: 760_70.
19 de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How
to measure comorbidity. A critical review of available methods.
J Clin Epidemiol 2003; 56: 221_9.
|